TUESDAY, Oct. 8, 2024 — Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according to a study published online Oct. 4 in Blood.
Surbhi Sidana, M.D…Original Article
Cilta-Cel Treatment Safe, Effective for Relapsed/Refractory Multiple Myeloma
TUESDAY, Oct. 8, 2024 — Ciltacabtagene autoleucel (cilta-cel) CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM) results in a deep and durable response, according to a study published online Oct. 4 in Blood.
Surbhi Sidana, M.D…
